Zydus Lifesciences Ltd

Zydus Lifesci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Zydus Lifesciences Ltd

₹ 1,078 -0.75%
29 May - close price
zyduscadila.com BSE: 532321 NSE: ZYDUSLIFE
About

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Key Points

Business Segments

Website BSE NSE
  • Market Cap ₹ 1,08,442 Cr.
  • Current Price ₹ 1,078
  • High / Low ₹ 1,116 / 836
  • Stock P/E 29.4
  • Book Value ₹ 235
  • Dividend Yield 0.09 %
  • ROCE 16.6 %
  • ROE 16.5 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 8.10% over past five years.
  • Earnings include an other income of Rs.1,501 Cr.
  • Company has high debtors of 270 days.
  • Working capital days have increased from 186 days to 315 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty Next 50

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
2,579 2,956 2,159 2,371 3,332 4,160 2,621 2,516 5,820 2,588 2,871 2,284 3,741
1,807 1,815 1,510 1,672 1,763 1,787 1,678 1,867 2,047 2,003 1,719 2,085 1,752
Operating Profit 772 1,141 649 699 1,569 2,373 942 648 3,773 585 1,152 199 1,989
OPM % 30% 39% 30% 29% 47% 57% 36% 26% 65% 23% 40% 9% 53%
47 82 534 107 352 107 327 78 185 157 542 414 388
Interest 85 90 91 104 106 115 96 97 155 138 114 116 116
Depreciation 120 121 125 128 131 131 134 132 128 130 136 144 151
Profit before tax 615 1,012 968 574 1,685 2,234 1,039 497 3,675 475 1,444 352 2,111
Tax % 20% 23% 17% 22% 17% 24% 24% 5% 23% 19% 20% 16% 18%
491 781 805 450 1,405 1,701 790 471 2,814 385 1,157 296 1,722
EPS in Rs 4.85 7.71 7.95 4.45 13.96 16.90 7.85 4.68 27.96 3.82 11.49 2.95 17.11
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
5,284 7,032 3,231 5,810 6,037 6,347 7,780 7,982 8,732 10,819 15,116 11,484
3,750 4,454 2,909 4,164 4,400 4,916 5,468 6,061 6,277 6,760 7,380 7,559
Operating Profit 1,535 2,578 322 1,646 1,637 1,432 2,312 1,921 2,454 4,059 7,736 3,925
OPM % 29% 37% 10% 28% 27% 23% 30% 24% 28% 38% 51% 34%
184 174 582 208 598 848 -102 -144 345 1,076 696 1,501
Interest 43 26 11 64 90 234 71 135 278 391 464 483
Depreciation 212 221 251 293 358 429 451 479 489 504 524 561
Profit before tax 1,465 2,504 642 1,497 1,787 1,617 1,688 1,164 2,032 4,240 7,445 4,382
Tax % 13% 19% -3% 27% 17% 13% 13% 26% 25% 19% 22% 19%
1,271 2,038 662 1,091 1,486 1,413 1,476 858 1,529 3,442 5,775 3,560
EPS in Rs 12.42 19.90 6.47 10.66 14.51 13.80 14.42 8.38 15.11 34.20 57.39 35.38
Dividend Payout % 19% 16% 50% 33% 24% 25% 24% 30% 40% 9% 19% 3%
Compounded Sales Growth
10 Years: 5%
5 Years: 8%
3 Years: 10%
TTM: -24%
Compounded Profit Growth
10 Years: 6%
5 Years: 18%
3 Years: 32%
TTM: -36%
Stock Price CAGR
10 Years: 13%
5 Years: 12%
3 Years: 28%
1 Year: 16%
Return on Equity
10 Years: 17%
5 Years: 19%
3 Years: 23%
Last Year: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 102 102 102 102 102 102 102 102 101 101 101 101
Reserves 4,423 6,174 6,516 7,643 8,467 11,158 12,642 13,138 13,538 15,616 21,090 23,571
1,450 1,223 2,940 2,872 3,583 3,695 3,920 2,665 4,825 6,178 8,342 7,442
1,362 1,424 1,489 1,546 1,519 1,597 1,799 1,835 2,099 2,190 2,785 2,766
Total Liabilities 7,337 8,923 11,047 12,164 13,671 16,552 18,464 17,740 20,564 24,085 32,317 33,880
1,768 2,155 2,352 2,680 3,932 4,109 4,112 4,336 4,184 4,369 4,202 5,084
CWIP 367 297 678 659 675 553 570 384 739 634 1,188 621
Investments 2,209 2,318 3,924 3,618 4,195 6,404 6,471 5,118 4,879 7,283 11,492 11,478
2,993 4,154 4,093 5,206 4,868 5,486 7,310 7,902 10,761 11,798 15,435 16,696
Total Assets 7,337 8,923 11,047 12,164 13,671 16,552 18,464 17,740 20,564 24,085 32,317 33,880

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,084 1,954 867 288 581 1,181 2,227 1,311 1,078 2,000 3,114 2,234
-577 -1,016 -2,480 28 -713 55 -2,714 768 -1,959 -1,832 -4,504 570
-387 -923 1,366 -149 65 -967 255 -1,710 827 -301 1,384 -2,580
Net Cash Flow 120 14 -247 167 -67 268 -231 369 -54 -132 -5 224
Free Cash Flow 781 1,383 94 -311 -140 589 1,701 794 420 1,434 2,257 1,351
CFO/OP 83% 92% 304% 35% 55% 97% 108% 82% 60% 71% 58% 84%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 73 89 105 79 128 141 89 104 147 160 197 270
Inventory Days 178 127 338 284 288 261 276 245 205 195 236 222
Days Payable 148 174 361 173 137 161 175 135 120 129 149 150
Cash Conversion Cycle 102 42 82 190 279 241 191 214 232 227 284 342
Working Capital Days 6 38 -101 37 81 55 50 105 164 167 74 315
ROCE % 27% 38% 8% 15% 16% 14% 12% 10% 14% 23% 31% 17%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Manufacturing Facilities
Number

Log in to view insights

Please log in to see hidden values.

Login
US ANDA Approvals during the year (Final & Tentative)
Number
US ANDAs Filed during the year
Number
R&D Spend as % of Revenue
%
India Field Force Strength
Number
Chronic Mix in India Formulations Business
%
US Market Prescriptions Rank (IQVIA)
Rank
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
74.98% 74.98% 74.98% 74.98% 74.98% 74.98% 74.98% 75.00% 75.00% 75.00% 75.00% 75.00%
4.04% 4.85% 4.99% 5.72% 5.59% 7.52% 7.53% 7.31% 7.13% 7.34% 7.06% 6.95%
13.44% 13.01% 12.96% 12.55% 12.56% 10.59% 10.61% 10.95% 11.09% 10.86% 11.08% 11.20%
0.07% 0.07% 0.07% 0.07% 0.07% 0.05% 0.05% 0.05% 0.04% 0.00% 0.00% 0.00%
7.47% 7.07% 6.99% 6.66% 6.81% 6.85% 6.85% 6.69% 6.74% 6.81% 6.86% 6.86%
No. of Shareholders 3,11,7642,97,9533,06,4952,94,3243,36,3093,70,8633,65,3563,71,6193,86,1273,96,1054,03,2664,18,314

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls